Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L P Fernandez

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Analyst|March 11, 1999
Monitoring the elimination of gadolinium-based pharmaceuticals. Cloud point preconcentration and spectrophotometric determination of Gd(III)-2-(3,5-dichloro-2-pyridylazo)-5-dimethylaminophenol in urineM F Silva, L P Fernandez, R A Olsina
Experimental Hematology|August 1, 1995
Does thalidomide affect IL-2 response and production?L P Fernandez, P G Schlegel, J Baker, et al.
Human Mutation|June 20, 2008
SLC45A2: a novel malignant melanoma-associated geneL P Fernandez, R L Milne, G Pita, et al.
Blood|October 15, 1994
Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex moleculesP G Schlegel, R Aharoni, D E Smilek, et al.
Experimental Hematology|December 1, 1993
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cellsI G Schmidt-Wolf, P Lefterova, B A Mehta, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Analyst|March 11, 1999
Monitoring the elimination of gadolinium-based pharmaceuticals. Cloud point preconcentration and spectrophotometric determination of Gd(III)-2-(3,5-dichloro-2-pyridylazo)-5-dimethylaminophenol in urineM F Silva, L P Fernandez, R A Olsina
Experimental Hematology|August 1, 1995
Does thalidomide affect IL-2 response and production?L P Fernandez, P G Schlegel, J Baker, et al.
Human Mutation|June 20, 2008
SLC45A2: a novel malignant melanoma-associated geneL P Fernandez, R L Milne, G Pita, et al.
Blood|October 15, 1994
Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex moleculesP G Schlegel, R Aharoni, D E Smilek, et al.
Experimental Hematology|December 1, 1993
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cellsI G Schmidt-Wolf, P Lefterova, B A Mehta, et al.
Pageof 1